Navigation Links
ReBuilder Medical (RBRM) Neuropathy Market Doubles to $5 Billion
Date:1/16/2009

CHARLES TOWN, W.Va., Jan. 16 /PRNewswire-FirstCall/ -- The US neuropathic pain market consists of 4.7 million patients, and is expected to grow to more than 6.1 million patients, and be valued at $5.1 billion in 2018.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO)

David B. Phillips, Ph.D. reports "We have not experienced the same economic down turn as other businesses because our market is growing."

John Johnson, Marketing Manager, has increased the ability of the company to expand its sales department in a novel way. "We have provided our inside sales reps with a special VOIP phone to use at home that give them the same access to answering the phone as they have in the office. We pay them on a commission basis and that has given us more sales at less cost. I fully expect sales to move to $6 million in 2009."

About ReBuilder Medical Technologies, Inc.:

ReBuilder Medical Technologies, Inc (Pink Sheets: RBRM) is an emerging medical device manufacturer of innovative technologies founded by world renowned medical device inventor David B. Phillips, Ph.D. ReBuilder Medical's flagship product is its FDA registered ReBuilder System for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery powered medical product that provides a new non-surgical treatment for diabetic peripheral neuropathy which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.

More information on ReBuilder Medical and its neuropathy products can be found at: www.rebuildermedical.com.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.


'/>"/>
SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
2. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
3. ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products
4. ReBuilder Medical Technologies, Inc. Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006, Including Record Daily Sales in September 2007
5. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
6. ReBuilder Medical Technologies, Inc. Announces Agreement with Internet Marketer Helio Health; Anticipates 12% Additional Profit
7. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
8. ReBuilder Medical Technologies, Inc. Increases Manufacturing Space to Meet Demand
9. ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support
10. ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment
11. ReBuilder Medical Technologies, Inc. Announces Record Sales Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... In 2014, Harvard researchers published ... approximately 800 deaths from prostate cancer, the researchers found that men who had undergone ... to get fatal prostate cancer. Although the increased risks are small, they seem to ...
(Date:2/28/2017)... Pekin, IL (PRWEB) , ... February 28, 2017 ... ... over the past decade, has challenges as they transition from military to civilian ... population of over two million who experience poorer health and greater occurrence of ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Robert E. ... large medical group. But his impoverished upbringing and life experiences could have led him ... a Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares ...
(Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, Dr. A. Rassouli, ... that occurs when the bacteria in plaque infect the gums and other tissues supporting ... and root planing or SRP, and can include surgical therapies if the condition has ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine ... programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce ... hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... ... has announced the addition of the "Ovarian Cancer Drugs Price Analysis ... The latest research Ovarian Cancer Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: ... clinical attributes? How are they positioned in the Global Ovarian Cancer market? ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. (Nasdaq: ... will report its fourth quarter and year end ... 7, 2017.  Rigel senior management will follow the ... at 5:00pm Eastern Time (2:00pm Pacific Time) to ... access the live conference call by dialing 855-892-1489 ...
(Date:2/28/2017)... FRANCISCO , February 27, 2017 ... D BioMedical assets for ... LOI contemplates capital infusion into Amarantus ...   Amarantus names four new appointees to its Board of ... SeD Biomedical Inc. (SeD Biomedical) , a ...
Breaking Medicine Technology: